---
title: Probiotic cocktail delays Parkinson progression
nct_id: NCT07619560
phase: NA
status: RECRUITING
sponsor: Taipei Medical University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07619560"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07619560"
last_fetched: "2026-06-02T14:00:50.923Z"
source: "Parkinson's Pathways (curated)"
---
# Probiotic cocktail delays Parkinson progression

**Goal (in five words):** Probiotic cocktail delays Parkinson progression

**Official Title:** Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease - Use Preclinical Human Trials to Confirm the Impact of the Optimal "Probiotic Y7, Tryptophan and Branched-chain Amino Acid" Cocktail Formula on Early Stage Parkinson's Disease Patient

**Trial ID:** [NCT07619560](https://clinicaltrials.gov/study/NCT07619560)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Taipei Medical University
- **Target Enrollment:** 120 participants
- **Start Date:** 2025-05-20
- **Completion Date:** 2027-08-31
- **Conditions:** Parkinson Disease (PD), Gut Microbiota, Probiotic
- **Interventions:** Y7, Placebo
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

The trial aims to slow early Parkinson's progression by reshaping the gut microbiome and related metabolites that may influence brain inflammation and dopamine pathways. Participants take a 12-week oral Y7 probiotic cocktail with added tryptophan and branched-chain amino acids, which is designed to boost beneficial gut bacteria and change amino acid levels that can affect neurotransmitter production and inflammation; because aromatic amino acids and BCAAs can compete with levodopa for absorption and transport, the study will watch for any changes in people’s medication response. Enrollment is open to adults 30 to 85 years old with early-stage PD (Hoehn and Yahr 1-3), MRI-confirmed striatal degeneration, who respond to Parkinson’s medications, are free of major acute illnesses or certain gut infections, not pregnant or breastfeeding, and able to complete the 12-week protocol.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Subject Inclusion Criteria:

1. Age between 30-85 years old.
2. Diagnosed with early-stage Parkinson's disease (Hoehn and Yahr scale stage 1-3).
3. Brain MRI confirms striatal degeneration in the basal ganglia region, with no history of stroke.
4. Responds to Parkinson's disease-related medications (e.g., Levodopa).
5. Free of any major or acute illnesses.
6. Able to comply with the 12 weeks intervention and required assessments for the study.

Exclusion Criteria:

1. Unable to complete interviews or has mobility issues.
2. Presence of major or acute illness before or during the study.
3. Co-existing intestinal co-infections, such as CDI, E. coli, Salmonella, Shigella, Campylobacter, plague, or cytomegalovirus.
4. Allergic to the intervention product.
5. Pregnant or breastfeeding women.
```

## Locations (1)

- Taipei Medical University Hospital, Taipei, Taiwan _(25.0531, 121.5264)_
  - Taipei Medical University Hospital — (CONTACT) — +886 +2 27372181 — ihc@h.tmu.edu.tw

## Central Contacts

- Hui Yu Huang, PhD — (CONTACT) — 02-27361661 — maggieh323@tmu.edu.tw

---

*Canonical: https://parkinsonspathways.com/trial/NCT07619560*  
*HTML version: https://parkinsonspathways.com/trial/NCT07619560*  
*Source data: https://clinicaltrials.gov/study/NCT07619560*